首页>投融资
Biomica
未透露
Biomica ltd, owned by Evogene Ltd is a biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated Computational Predictive Biology platform to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders.In April 2023, Biomica Ltd closed a financing round of $20 million.In December 2022, Biomica Ltd and a subsidiary of Evogene Ltd announced the signing of a definitive agreement for a $20 million financing round, to be led by Shanghai Healthcare Capital (SHC)
基本信息
-
公司全称Biomica Ltd
-
类型微生物创新疗法开发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数15人以下
-
地址13 Gad Feinstein st. Park Rehovot REHOVOT; IL; Telephone: +97289311900;
-
联系电话972-8-9311900
-
邮箱Info@biomicamed.com
-
成立时间2016-02-01
投融资
-
2023-04-27未透露2000万美元Shanghai Healthcare Capital
-
2022-12-22未透露未透露未透露
相关投融资企业
A轮
Ouro Medicines是一家免疫重置公司,通过结合科学专业知识、通过临床推进细胞耗竭疗法的跟踪记录以及强大的管道来正面应对慢性免疫介导的疾病。Ouro最领先的候选产品是OM336,这是一种最近从康诺亚生物获得许可的BCMA靶向的双特异性TCE。
A轮
RhyGaze开发一种新的基因疗法,旨在恢复患者的视力。该公司的治疗技术将光传感器基因专门传递给失去光敏感性的视锥细胞,并修复其检测光的能力,使医疗保健行业能够为失明患者提供视力恢复。
未公开
Thetis Pharmaceuticals LLC is a pharmaceutical company focused on the development of prescription drugs for diabetes, hypertriglyceridemia and dyslipidemia. Thetis's proprietary HEALER technology (High Efficiency Amino Lipid Enabled Release) uses transformative ionic chemistry to revitalize proven therapeutic agents and generated solid, stable APIs.In July 2021, Thetis Pharmaceuticals LLC announced the launch of a new program in cancer TP-317, which is a Resolvin E1 therapy for the treatment of solid tumour cancers published in the Journal of Experimental Medicine.In May 2013, the company raised $5.7 million through a series A financing.In September 2011, Thetis secured first round funding. At that time, the company planned to secure additional capital in the second half of 2012